Drug intelligence / Profile preview

cyclamate

Development stage
Unknown
Lead developer
Abbott
Modality
Small Molecules
Administration
Oral
01

Overview

Cyclamate is a non-nutritive artificial sweetener approximately 30–50 times sweeter than sucrose. It is most commonly used as the sodium or calcium salt of cyclohexylsulfamic acid. Cyclamates are stable to heat and soluble in water. They are widely used in food and beverage products such as baked goods, confections, desserts, soft drinks, preserves and salad dressings—often in combination with other sweeteners like saccharin to mask off-tastes and enhance sweetness synergy[1][2][3]. Cyclamate exerts its effect by interacting with the sweet taste receptor subunit TAS1R3 (T1R3), acting as an agonist at this receptor[5]. Discovered in 1937 by Michael Sveda at the University of Illinois[9], it was initially marketed for diabetics but later found widespread use due to its low cost and stability. Safety concerns led to bans in some countries (notably the US), but it remains approved for use in over 100 countries including those within the European Union[2][3].

Brand names
SucarylSüssinaPolysweetPolysettSweetyHuxol
Other names
sodium cyclamatecalcium cyclamateE952E-952E 952sodium N-cyclohexylsulfamic acid
02

Targets

TAS1R3 (Sweet taste receptor T1R3 subunit)

Beyond the preview

Go deeper on cyclamate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclamate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call